MANNKIND CORP Selling and Marketing Expense
MANNKIND CORP (MNKD) reported Selling and Marketing Expense of $19.85 million for the 12-month period ending 2016-12-31, per its 10-K filed 2017-03-16.
Discontinued › Expense Statement › Operating Expenses
us-gaap:SellingAndMarketingExpense · last filed 2017-03-16
- MANNKIND CORP selling and marketing expense for the quarter ending 2016-12-31 was $8.83M.
- MANNKIND CORP selling and marketing expense for the quarter ending 2016-09-30 was $7.00M, a 1281.66% increase year-over-year.
- MANNKIND CORP selling and marketing expense for the quarter ending 2015-12-31 was -$29.00K.
- MANNKIND CORP selling and marketing expense for the quarter ending 2015-09-30 was $507.00K.
- MANNKIND CORP selling and marketing expense for fiscal 2016 was $19.85M, a 1151.04% increase from fiscal 2015.
- MANNKIND CORP selling and marketing expense for fiscal 2015 was $1.59M, a 55.37% decline from fiscal 2014.
- MANNKIND CORP selling and marketing expense for fiscal 2014 was $3.56M.
| Period end | Selling and Marketing Expense 3 month | Selling and Marketing Expense 6 month | Selling and Marketing Expense 9 month | Selling and Marketing Expense 12 month |
|---|---|---|---|---|
| 2016-12-31 | $8.83M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-16 | $15.84M derived: sum of 2 quarters · filed 2017-03-16 | $19.85M 10-K · filed 2017-03-16 | |
| 2016-09-30 | $7.00M 10-Q · filed 2016-11-09 | $11.02M 10-Q · filed 2016-11-09 | ||
| 2015-12-31 | -$29.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-16 | $478.00K derived: sum of 2 quarters · filed 2017-03-16 | $1.59M 10-K · filed 2017-03-16 | |
| 2015-09-30 | $507.00K 10-Q · filed 2016-11-09 | $1.62M 10-Q · filed 2016-11-09 | ||
| 2014-12-31 | $3.56M 10-K · filed 2017-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |